JAK1 and acute myeloid leukemia: The JAK1/2 inhibitor Ruxolitinib has restored sensitivity to the B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) inhibitor venetoclax in AML patient cells [30].